Direct Meds GLP-1 vs Fridays
Recorded prices, access and terms.
Decision table
The entries below are recorded provider statements unless a regulatory source is linked. A provider webpage does not independently verify its licenses or quality. Direct Meds GLP-1 source · Fridays source.
| Compare | Direct Meds GLP-1 | Fridays |
|---|---|---|
| Recorded medication/program subtotal | Recorded medication and program subtotal — semaglutide: $249/month; tirzepatide: $297/month. Other required fees, labs, dose changes and renewal terms: unconfirmed. This is not a verified all-in treatment cost. | Monthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed. |
| Full required monthly cost | Unconfirmed: consultation, labs, membership, dose changes and shipping must be checked | Unconfirmed: consultation, labs, membership, dose changes and shipping must be checked |
| Drug type listed | Compounded | Brand-name and compounded |
| Consultation | Included in the record; current conditions unconfirmed | Included in the record; current conditions unconfirmed |
| Pharmacy license | Not independently verified. Obtain the dispensing pharmacy name and verify its state license. | Not independently verified. Obtain the dispensing pharmacy name and verify its state license. |
| Reported states | 45; confirm eligibility and clinician licensing in your state | 49; confirm eligibility and clinician licensing in your state |
| Cancellation | Cancellation reported; notice, minimum term and refund conditions unconfirmed | Cancellation reported; notice, minimum term and refund conditions unconfirmed |
| Clinician/support as reported | Licensed providers | Licensed providers, health coaching, nutrition support |
| Recorded provider check | 2026-09-13 | No date recorded |
Which should you choose?
Ask each provider for the full cost at your prescribed dose, required labs and visits, the dispensing pharmacy, the clinician's state license, renewal charges and written refund terms. Compare those answers with your clinician.
Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or quality before marketing. FDA source and recommendations.
Direct Meds GLP-1: evidence and terms
Recorded FDA letter (2025-09-09): FDA found claims on directmeds.com that its compounded semaglutide and tirzepatide contain 'the same active ingredient' as the brand drugs false or misleading, making the products misbranded under FD&C Act sections 502(a) and 502(bb). FDA letter.
Read Direct Meds GLP-1's sourced record · Direct Meds GLP-1 source
Fridays: evidence and terms
Compare the full provider directory · Compare recorded price subtotals